Cardiac Safety-ECG Monitoring

Identify cardiac risks sooner to support more timely go/no go decisions

Increased regulatory demands to identify evidence of cardiac risk for any drug make it imperative to initiate ECG monitoring as early as possible in your development process. Timing is critical so that you can make go/no go decisions before investing significant time and money.

banner_red testtubes

Real-time access to ECG reports and summary data using our online portal, with 24/7 investigator and site helpline

Flag risks now to prevent complications later

ECG monitoring enables you to proactively assess cardiac safety risks, which means you can stay on top of cardiac safety concerns that could derail your product’s future and avoid the costs of leaving signals undetected until later, larger studies.

Tools and expertise to help you manage risk

Quintiles has the industry’s largest staff of cardiologists to review, analyze and adjudicate each ECG, and we combine high-capacity, cost-effective ECG monitoring with drug development expertise. The result? An interdisciplinary team that helps you make better decisions earlier – and meet regulatory expectations at each step of development, from First-in-Human studies to regulatory submission.

We provide:
  • Real-time access to ECG reports and summary data using our online portal, with 24/7 investigator and site helpline.
  • A proprietary, patent-pending system to flag, manage and quickly resolve data queries.
  • Central reading standards that exceed ICH/FDA/EMA guidelines.

The power of possibilities

We’ve built an unmatched set of ECG monitoring capabilities and a cost-effective process that give sponsors a head start on successful trials.

Related services

Clinical monitoring
Risk-based monitoring
Clinical data management